Author Archives: donttradeourlivesaway

IPR policy: Noble intent but challenges galore

By Zakhir Thomas, The Deccan Herald | May 19, 2016 The national Intellectual Property Rights (IPR) policy aims to create an innovative India. The policy is predicated upon the principle that intellectual property protection is necessary to spur innovation. 

Posted in IPR, IPR policy, Uncategorized | Leave a comment

Who Gains from the Modi Government’s Intellectual Property Rights Policy?

The new policy is clearly informed by conservative pro-IP ideology, which big capital promotes in order to gain from current developments in science and technology. By Dinesh Abrol, The Wire | May 22, 2016 The National Intellectual Property Rights policy … Continue reading

Posted in IPR, IPR policy, Uncategorized | Leave a comment

Why New IPR Policy Is Inadequate

Pressure from US Is Unstated Reason By K M GopaKumar, The Economic & Political Weekly| Vol. 51, Issue No. 21, 21 May, 2016 By proposing a maximalist approach towards intellectual property rights, the new IPR policy announced by the government is not … Continue reading

Posted in IPR, IPR policy, Uncategorized | Leave a comment

TB patients protest outside health ministry, promised proper drug regimes from July

By Aradhna Wal, DNA | ARADHNA WAL | Fri, 20 May 2016 Antiretroviral therapy (ART) centres for HIV patients are without the daily FDCs and the five selected states have not yet seen the rollout “due to delays in procurement of … Continue reading

Posted in Tuberculosis (TB), Uncategorized | Leave a comment

Leaked letters show trade tensions over Colombian CL for Novartis’ Gleevec

By Eric Sagonowsky, FiercePharma | May 17, 2016 Two leaked letters written by a representative of the Embassy of Colombia in Washington, DC, and sent to officials in that country showcase deep tensions over a plan by the government there to … Continue reading

Posted in Compulsory Licensing, Patent, Uncategorized | Leave a comment

Colombia battles world’s biggest drugmaker over cancer drug

By Joshua Goodman and Linda A. Johnson, The Washington Post | May 18, 2016 BOGOTA, Colombia — Colombia’s government is giving pharmaceutical giant Novartis a few weeks to lower prices on a popular cancer drug or see its monopoly on production of … Continue reading

Posted in Compulsory Licensing, Patent, Uncategorized | Leave a comment

India allows Gilead to patent Hepatitis C drug. Here’s why it is cruel

By Vishakh Unnikrishnan, The CatchNews | May 14, 2016 Landing a blow to efforts to make vital drugs more affordable, the Indian Patent Office has granted the American pharmaceutical company Gilead a patent for sofosbuvir, which is used to treat … Continue reading

Posted in Hepatitis C, Patent Opposition, Sofosbuvir, Uncategorized | Leave a comment